Semaglutidedosage

Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals.

Inject subcutaneously in the abdomen, thigh or upper arm.

In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment.

Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage.

The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.

The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly.

2.1 Important

Monitoring and Administration Instructions

In patients with type 2 diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment.

Prior to initiation of WEGOVY, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.

Inspect WEGOVY visually prior to each injection. Only use if solution is clear, colorless, and contains no particles.

Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity.

Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.

Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without dose adjustment.

2.2 Recommended

Dosage in Adults Dosage Initiation and Escalation

Initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly. Then follow the dose escalation schedule presented in Table 1 to minimize gastrointestinal adverse reactions.

If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. Table 1. Recommended Dosage Regimen for Adults Treatment Weeks Once weekly Subcutaneous Dosage Initiation 1 through 4 0.25 mg Escalation 5 through 8 0.5 mg 9 through 12 1 mg 13 through 16 1.7 mg Maintenance 17 and onward 1.7 mg or 2.4 mg Maintenance Dosage

The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider treatment response and tolerability when selecting the maintenance dosage.

2.3 Recommended

Dosage in Pediatric Patients Aged 12 Years and Older Dosage Initiation and Escalation

Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions.

If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.

The 0.25 mg, 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages. Table 2. Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older Treatment Weeks Once weekly Subcutaneous Dosage Initiation 1 through 4 0.25 mg a Escalation 5 through 8 0.5 mg a 9 through 12 1 mg a 13 through 16 1.7 mg b Maintenance 17 and onward 2.4 mg a Not approved as maintenance dosages b See Dosage Modifications for Adverse Reactions Maintenance Dosage

The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly. Dosage Modifications for Adverse Reactions

If patients do not tolerate the 2.4 mg once weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once weekly.

Discontinue WEGOVY if the patient cannot tolerate the 1.7 mg once-weekly dosage.

2.4 Recommendations

Regarding Missed Dose

If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.

If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.